Cabio Biotech Wuhan Stock Shares Outstanding
| 688089 Stock | 18.09 0.25 1.40% |
Cabio Biotech Wuhan fundamentals help investors to digest information that contributes to Cabio Biotech's financial success or failures. It also enables traders to predict the movement of Cabio Stock. The fundamental analysis module provides a way to measure Cabio Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cabio Biotech stock.
As of January 6, 2025, Common Stock Shares Outstanding is expected to decline to about 130.2 M. Cabio | Shares Outstanding |
Cabio Biotech Wuhan Company Shares Outstanding Analysis
Cabio Biotech's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cabio Biotech Shares Outstanding | 168.31 M |
Most of Cabio Biotech's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cabio Biotech Wuhan is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Cabio Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Cabio Biotech Wuhan has 168.31 M of shares currently outstending. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The shares outstanding for all China stocks is notably lower than that of the firm.
Cabio Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cabio Biotech's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cabio Biotech could also be used in its relative valuation, which is a method of valuing Cabio Biotech by comparing valuation metrics of similar companies.Cabio Biotech is currently under evaluation in shares outstanding category among its peers.
Cabio Fundamentals
| Return On Equity | 0.0733 | ||||
| Return On Asset | 0.0383 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 2.86 B | ||||
| Shares Outstanding | 168.31 M | ||||
| Shares Owned By Insiders | 50.75 % | ||||
| Shares Owned By Institutions | 4.86 % | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 5.98 X | ||||
| Revenue | 443.8 M | ||||
| Gross Profit | 179.62 M | ||||
| EBITDA | 160.2 M | ||||
| Net Income | 91.37 M | ||||
| Total Debt | 12.1 M | ||||
| Book Value Per Share | 9.07 X | ||||
| Cash Flow From Operations | 68.89 M | ||||
| Earnings Per Share | 0.68 X | ||||
| Target Price | 17.0 | ||||
| Number Of Employees | 508 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 3.02 B | ||||
| Total Asset | 1.61 B | ||||
| Retained Earnings | 421.34 M | ||||
| Working Capital | 596.35 M | ||||
| Net Asset | 1.61 B | ||||
| Last Dividend Paid | 0.2 |
About Cabio Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cabio Biotech Wuhan's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cabio Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cabio Biotech Wuhan based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Cabio Stock
Cabio Biotech financial ratios help investors to determine whether Cabio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cabio with respect to the benefits of owning Cabio Biotech security.